Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PR ...

Clinical Trial Results - MeiraGTx's rAAV8.hRKp.AIPL1 gene therapy has shown efficacy in all 11 children (aged 1-4 years) treated for AIPL1 Retinal Dystrophy (LCA4) [3] - In the unilateral treatment group (4 patients), durable efficacy has been observed for up to 4 years [3] - In the unilateral treatment group, visual acuities of treated eyes improved to a mean of 0.9 LogMAR, while untreated eyes showed no improvement [6] - All 7 bilaterally-treated children showed meaningful improvements in functional vision, visual acuity, and neurophysiology [14] - Binocular visual acuities in bilaterally-treated children improved to a mean of 1.0 LogMAR after a mean follow-up of 5 months [14] Regulatory Status - MeiraGTx was granted an Innovation Passport designation in the UK for rAAV8.hRKp.AIPL1 [16] - MeiraGTx has been advised to file for 'Marketing Authorization Under Exceptional Circumstance' in the UK based on data from 11 children [16] - AAV-AIPL1 has orphan status in the US and EU and Rare Pediatric Disease Designation in the US, making it eligible for a PRV voucher upon approval [16] Overall Impact - Treatment with rAAV8.hRKp.AIPL1 has resulted in improvements in visual function, retinal function, and visual behavior in treated children [15] - These visual improvements have led to life-changing benefits in communication, behavior, schooling, mood, psychological well-being, and social integration [15]

Core Viewpoint - Beijing Tongrentang Medical Investment Co., Ltd. (Tongrentang Medical) has submitted its IPO application for the third time in a year, aiming to become the fourth listed company under the Tongrentang Group, which includes Tongrentang, Tongrentang Technology, and Tongrentang Guoyao [1][8] Company Overview - Tongrentang Medical, established in 2015, is the largest private traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of outpatient and inpatient visits in 2024 [1] - The company ranks second in the private traditional Chinese medicine medical service industry with a market share of 0.2% in total medical service revenue, accounting for 46.5% of the market size of the traditional Chinese medicine medical service industry in China [1] Financial Performance - Revenue from Tongrentang Medical has shown growth from approximately 911 million yuan in 2022 to 1.175 billion yuan in 2024, with net profits turning positive in 2022 after a series of acquisitions [3][4] - The company reported net profits of -9.23 million yuan in 2022, 42.63 million yuan in 2023, and 46.19 million yuan in 2024 [3] Acquisition Strategy - The company's growth has been primarily driven by acquisitions, with plans to acquire five profit-making medical institutions by the end of 2029, focusing on economically active regions such as Beijing and the Yangtze River Delta [5][8] - Tongrentang Medical has increased its total number of medical visits from 1.3 million in 2022 to 3 million in 2024, with a compound annual growth rate of 51.9% [4] Debt and Financial Risks - The company's debt ratio has risen significantly from less than 10% in 2021 to 45.2% in 2024, raising concerns about the sustainability of its growth [2][7] - As of April 30, 2024, the total outstanding bank loans amounted to 142 million yuan, with a significant portion of its equity pledged to secure financing [7] Market Position and Competition - The number of participants in China's private traditional Chinese medicine medical service industry has increased from 2,525 in 2019 to 3,614 in 2024, indicating intensified competition [9] - Despite the competitive landscape, Tongrentang Medical benefits from the strong brand recognition of the "Tongrentang" name and has a well-established business model that includes medical services, management services, and health product sales [9] IPO Objectives - The funds raised from the IPO are intended for expanding the company's medical service network, enhancing service capabilities, repaying bank loans, and general corporate purposes [8] - The repeated submissions of the IPO application may indicate challenges in meeting market expectations or regulatory requirements [8]

"这周末快40度了，空调能提前送货安装吗？"家住江苏省南京市的秦女士即将入住新房，在苏宁易购购 买的2台空调原计划7月中旬才送货安装，而提前到来的高温让她措手不及，只能求助于专属"蓝朋友"。 苏宁易购家电管家王娇娇第一时间沟通协调物流仓库及帮客工程师，第二天即完成了两台空调的送货及 安装调试。"最近一周到店选购空调的顾客比之前多了一倍还不止，通过门店仓库联动，今天下单明天 就能送货，最快24小时就能让顾客用上空调，V4、V5会员还可获得一次空调免费清洗服务。"王娇娇 说。 7月2日，国家疾病预防控制局联合中国气象局发布首个全国高温健康风险预警，多地亮起代表"极高风 险"的红色警报。未来一周，华北南部、黄淮至江南、华南的大部地区都将体验"蒸桑拿"，山东、河 南、安徽、江苏、湖北、浙江等地还可能出现40℃及以上的酷热天气。多地夜间最低气温仍达30℃左 右，形成全天候的高温"围攻"之势。 持续高温点燃清凉家电消费，空调换新、清洗需求加速释放。苏宁易购清凉节推出爆款空调一口价，叠 加国补、厂补、苏宁补多重优惠后至高立省50%，其中1.5匹一级能效变频空调低至1599元，3匹客厅风 管机低至3999元。以旧换新单台空调 ...

据南京发布消息，首份"苏超"赛事影响力报告出炉。7月1日，从国家统计局江苏调查总队获悉，近期国家统 计局江苏调查总队对全省3189位常住居民开展的专题调研显示，江苏省城市足球联赛成功收获群众的关注度 与美誉度。赛事影响力与刺激消费互促共振。 香港特区政府公布"粤车南下"初步实施阶段，每日配额100辆车 香港特区政府7月2日公布"粤车南下"将于今年11月实施。香港特区政府运输及物流局局长陈美宝2日宣布， 经与广东省相关部门协商后达成共识，"粤车南下"计划争取于11月正式启动实施。初步实施阶段，每日配额 100辆车，车辆可驶入香港市区。 8月1日起，现金买黄金钻石超10万元需上报 7月2日消息，央行近日印发《贵金属和宝石从业机构反洗钱和反恐怖融资管理办法》（下称《管理办法》） 称，客户单笔或者日累计金额人民币10万元以上(含10万元)或者等值外币现金交易的，从业机构应当按照规 定在交易发生之日起5个工作日内向中国反洗钱监测分析中心提交大额交易报告。该办法自8月1日起施行。 全国首个！"无堂食外卖"标准来了 "苏超"赛事影响力报告：赛事经济成为激发城市消费活力的新引擎 近日，重庆市市场监管局制定发布了《无堂食外卖经 ...

Group 1 - Chongqing Steel (601005) has seen a significant rise in stock price, with its H-shares increasing by 130% recently, contrasting with its previous low of around 1 yuan last year [1][2] - The collective movement in steel stocks is attributed to recent production cuts in Tangshan and government meetings emphasizing the need to eliminate low-price competition and promote quality improvement [1][2] - The current production cuts in Tangshan are widespread but do not have a direct correlation with industry capacity reduction policies, leading to uncertainty about the future of capacity elimination in the steel sector [1][6] Group 2 - The recent surge in steel stocks has been driven by multiple favorable factors, including government policies aimed at reducing excess capacity and improving product quality [2][5] - The steel industry is characterized by a high concentration of low-priced and undervalued stocks, which tend to react strongly to news regarding capacity reduction [2][5] - The profitability of steel companies is closely linked to steel prices, which affects their willingness to reduce production; recent data shows that the steel industry achieved a profit of 31.69 billion yuan in the first five months of 2025, surpassing the total profit of 29.19 billion yuan for the entire year of 2024 [5][6] Group 3 - The current market dynamics indicate that the overall supply-demand relationship in the steel industry has not undergone a significant shift, despite recent price fluctuations [4][8] - The focus of future policy efforts on capacity reduction may not necessarily target the steel industry, as the current overcapacity issues are more prevalent in emerging industries like new energy vehicles and photovoltaics [6][8] - The capacity reduction policies are expected to be more market-driven and regionally tailored, avoiding a one-size-fits-all approach that could lead to market volatility [7][8]

PYX-201 Mechanism and Target - PYX-201 is a first-in-concept extracellular-cleaving ADC targeting EDB+FN, a non-cellular component of the tumor extracellular matrix [6, 7] - EDB+FN is highly overexpressed in various solid tumors, releasing the payload extracellularly for direct tumor killing, bystander effect, and immunogenic cell death [10, 11] - PYX-201's unique mechanism of action (MOA) may address a primary cause of drug resistance by altering the ECM [16] Clinical Trial and Tolerability - Phase 1 dose escalation study included 80 patients with 10 solid tumor types [29] - PYX-201 demonstrated a favorable tolerability profile with a low treatment discontinuation rate of 1% [6, 39] - The identified dose range for further evaluation is 3.6 - 5.4 mg/kg [6, 34] Efficacy and Responses - An overall response rate (ORR) of 26% was observed in 6 responding tumor types (n=31) at the identified dose range of 3.6-5.4 mg/kg [6, 43] - In HNSCC patients within the 3.6 – 5.4 mg/kg dose range, a 50% ORR and 100% disease control rate (DCR) were observed [6, 54] - Median time on study in Phase 1 Part 1 was approximately 12 weeks [50, 51] Future Development and Catalysts - A clinical trial collaboration will evaluate PYX-201 in combination with KEYTRUDA® (pembrolizumab) [18] - Multiple clinical catalysts are expected in the next 6-18 months, including readouts from HNSCC monotherapy and early line combination studies [6, 65] - As of Q3 2024, the company has $146 million in cash, providing runway into 2H 2026 [87]

Company Overview - enCore Energy aims to produce 3 million pounds of U3O8 per year by the end of 2026 and 5 million pounds of U3O8 per year by the end of 2028 [26] - The company has a market capitalization of $835,566,936 USD as of February 12, 2024 [34] Production and Operations - Rosita Central ISR Uranium Processing Plant (CPP) restarted production in November 2023 and is expected to produce approximately 200,000 pounds of U3O8 per year [65, 92] - The Rosita CPP has a licensed production capacity of 800,000 pounds of U3O8 per year, with the potential to double capacity within existing licenses [67] - Alta Mesa CPP is planned for production in 2024, with an initial production target of approximately 500,000 pounds [16, 96] - The combined capacity of the company's three fully licensed CPPs (Rosita, Kingsville Dome, and Alta Mesa) is 3.6 million pounds of U3O8 per year [82] Resource Estimates - Alta Mesa and Mesteña Grande have total Measured and Indicated Mineral Resources of 1,570,000 tons at 0.109% U3O8, containing 3.41 million pounds of U3O8 [95] - Alta Mesa and Mesteña Grande have total Inferred Mineral Resources of 6,996,000 tons at 0.120% U3O8, containing 16.793 million pounds of U3O8 [95] - Dewey-Burdock Project has Measured and Indicated ISR Resources of 7,388,222 tons at an average grade of 0.116% U3O8, containing 17.12 million pounds [102] - Gas Hills Project has Measured & Indicated ISR mineral resources of 3.83 million tons at 0.101% eU3O8, attributable to 7.71 million pounds U3O8 [111] - Crownpoint & Hosta Butte Project has total Indicated Mineral Resource of 10.96 million tons at Grade eU3O8 0.117 %, attributable U3O8 is 25.70 million pounds [124] Market and Strategy - The company has four uranium sales agreements in place [23, 87] - The company is pursuing a non-core asset divestment strategy [25, 136] - The company is investing in new technologies like Prompt Fission Neutron (PFN) technology [25, 58, 137]

国外 1. 小摩：非农或重新点燃美国经济增长担忧，并加大美联储降息压力 美元交投稳定，因投资者在关键的美国非农就业报告出炉前按兵不动。经济学家预计，6月就业人口增 加11万人，低于5月的13.9万人，失业率预计将从4.2%上升至4.3%。摩根大通在一份报告中表示，这可 能会让对经济增长的担忧"重新成为人们关注的焦点"，并加大美联储加快降息时间表的压力。然而，他 表示，与就业相比，通胀离目标更远，因此美联储应在降息问题上保持谨慎立场。 2. 瑞银：特朗普对越南的20%关税处于预期范围的低端 瑞银经济学家William Deng在一份研究报告中说，美国对越南商品征收的20%关税处于预期范围的低 端。越南允许美国商品免税进入该国的决定"在很大程度上是意料之中的"，因为美国产品在技术和能源 等领域的更多准入应该有利于越南的经济增长。该贸易协议的细节对于确定对越南的经济影响至关重 要，尤其是对转运货物的影响，转运货物将面临40%的关税。今后一个关键的观察点是，是否有进一步 向美国和国际资本开放金融市场的细节。 3. 星展银行：美越贸易协议降低风险，但缺乏细节 星展银行高级经济学家Chua Han Teng说，美越贸易协 ...

Core Insights - WisdomTree, Inc. (WT) shares experienced a significant increase of 6.6%, closing at $12.25, with a notable trading volume, contributing to a total gain of 20.4% over the past four weeks [1][2]. Analyst Ratings - Morgan Stanley raised its price target for WisdomTree from $9.75 to $11.00 while maintaining an equal weight rating [2] - Northcoast Research upgraded WisdomTree from neutral to buy, setting a price target of $15.00 [2] - Goldman Sachs upgraded its rating from sell to neutral and increased the price target from $9.50 to $11.90, reflecting a wave of bullish sentiment among analysts [2] Earnings Expectations - WisdomTree is expected to report quarterly earnings of $0.17 per share, representing a year-over-year increase of 6.3% [3] - Revenue expectations stand at $111.06 million, which is a 3.8% increase compared to the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for WisdomTree has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - WisdomTree currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [4] Industry Context - WisdomTree operates within the Zacks Financial - Miscellaneous Services industry, where another company, Moody's (MCO), closed 1.1% lower at $497.12, with a 4.2% return over the past month [4]